Discrimination against trainees, increased platelet count and cancer risk

A recent study has shown that patients often display discriminatory behavior towards hematology and oncology trainees.

The researchers said the study highlights the need for new policies to address discriminatory behavior. This was the biggest story in hematology/oncology last week.

Another important story concerns a study that found that a high number of platelets was associated with an increased risk of cancer, particularly colon, lung, ovarian and stomach cancers.

Read these stories and many more in hematology/oncology below:

Trainees in hematology and oncology often face discrimination, study shows

Discriminatory behavior towards trainees in the field of hematology and oncology remains common and appears to be exhibited more often by patients than by staff members, according to the results of a study published in Open JAMA Network. Read more.

High platelet count associated with increased risk of certain cancers

According to a case-control study nested in Open JAMA Network. Read more.

Reporting: Lung cancer survival is improving, progress stagnates in the bosom, prostate cancer

A growing percentage of lung cancer cases are being diagnosed at an earlier stage, according to a new report from the American Cancer Society. People diagnosed with the disease also seem to live longer, Cancer statistics 2022 report showed. Read more.

Major movements: Two female oncologists talk about new jobs, children

There are many major life events that can be as exciting as they are demanding, such as starting the next stage of a career or having a child – two events that two fellow oncologists experienced at around the same time. Read more.

FDA lifts clinical hold of Allogene‘s CAR T–cell therapy trials

The FDA has lifted its clinical grip on a series of trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer. Read more.